Camurus AB/Skr CAMX
07:00
09:05
11:15
13:20
15:25
1D1W1MYTD1Y5YMAX
About Camurus AB
Camurus AB is a biopharmaceutical company headquartered in Lund, Sweden, specializing in the development of innovative pharmaceuticals for the treatment of serious and chronic diseases. The company's core offerings focus on proprietary drug delivery technologies, including FluidCrystal® technology, which enhances the therapeutic benefits and delivery of active ingredients. Camurus concentrates its efforts on areas such as addiction treatment, pain management, and oncology, aiming to improve patient outcomes through advanced formulations. The company operates in several international markets, leveraging strategic partnerships and a focused product pipeline to maintain its position within the biopharmaceutical industry. Its operations are characterized by a strong emphasis on research and development to sustain and expand its portfolio.
Ticker
Skr CAMX
Sector
Primary listing
XSTO
Employees
274
Headquarters
Lund, Sweden
Website
Camurus AB Metrics
BasicAdvanced
kr 31bn
45.32
kr 11.35
-
-
Price and volume
Market cap
kr 31bn
52-week high
kr 754.50
52-week low
kr 430.80
Average daily volume
188k
Financial strength
Current ratio
11.57
Quick ratio
10.884
Long term debt to equity
2.004
Total debt to equity
2.489
Interest coverage (TTM)
140.80%
Profitability
EBITDA (TTM)
816.247
Gross margin (TTM)
93.13%
Net profit margin (TTM)
30.45%
Operating margin (TTM)
36.37%
Effective tax rate (TTM)
20.96%
Revenue per employee (TTM)
kr 8,180,000
Management effectiveness
Return on assets (TTM)
11.41%
Return on equity (TTM)
17.25%
Valuation
Price to earnings (TTM)
45.315
Price to revenue (TTM)
13.646
Price to book
6.89
Price to tangible book (TTM)
6.89
Price to free cash flow (TTM)
37.741
Free cash flow yield (TTM)
2.65%
Free cash flow per share (TTM)
13.633
Growth
Revenue change (TTM)
10.03%
Earnings per share change (TTM)
23.61%
3-year revenue growth (CAGR)
29.98%
10-year revenue growth (CAGR)
34.40%
3-year earnings per share growth (CAGR)
78.41%
10-year earnings per share growth (CAGR)
5.88%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs